A feasibility study of varenicline for smoking cessation in bipolar patients with subsyndromal depression

Journal of Clinical Psychopharmacology

Volumn 33, Issue 6, 2013, Pages 821-823

  Frye, Mark A ^a   Ebbert, Jon O ^a   Prince, Courtney A ^a,b   Lineberry, Timothy W ^a   Geske, Jennifer R ^a   Patten, Christi A ^a  

^a MAYO CLINIC   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CARBON MONOXIDE; MOOD STABILIZER; VARENICLINE;

ALCOHOL CONSUMPTION; ANXIETY; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BREATH ANALYSIS; CLINICAL PRACTICE; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; FOLLOW UP; HUMAN; LETTER; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MORBIDITY; MORTALITY; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; PROBLEM SOLVING; SMOKING CESSATION; SUBSYNDROMAL DEPRESSION; SUICIDAL BEHAVIOR; SUICIDE ATTEMPT; TOBACCO DEPENDENCE; UNITED STATES; YOUNG MANIA RATING SCALE;

ADULT; BENZAZEPINES; BIPOLAR DISORDER; DEPRESSION; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINIC AGONISTS; QUINOXALINES; SMOKING CESSATION;

EID: 84888137100     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31829cc3cd     Document Type: Letter

References (17)

1. Lasser K, Boyd JW, Woolhandler S, et al. Smoking and mental illness: a population-based prevalence study. JAMA. 2000;284:2606-2610.
2. Oquendo MA, Galfalvy H, Russo S, et al. Prospective study of clinical predictors of suicidal acts after a major depressive episode in patients with major depressive disorder or bipolar disorder. Am J Psychiatry. 2004; 161:1433-1441.
3. Waxmonsky JA, Thomas MR, Miklowitz DJ, et al. Prevalence and correlates of tobacco use in bipolar disorder: data from the first 2000 participants in the Systematic Treatment Enhancement Program. Gen Hosp Psychiatry. 2005;27:321-328.
4. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47-55.
5. Wu BS, Weinberger AH, Mancuso E, et al. A preliminary feasibility study of varenicline for smoking cessation in bipolar disorder. J Dual Diagn. 2012;8:131-132.
6. Heatherton TF, Kozlowski LT, Frecker RC, et al. The Fagerstro? Test for Nicotine Dependence: a revision of the Fagerstro? Tolerance Questionnaire. Br J Addict. 1991; 86:1119-1127.
7. Mayo Clinic Nicotine Research Program. Smoke Free and Living It. Rochester, MN: Mayo Foundation for Medical Education and ResearchVNicotine Dependence Center Research Program; 2000.
8. Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD.: U.S. Department of Health and Human Services, Public Health Service; 2008.
9. SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine Tob Res. 2002;4:149-159.
10. Cox LS, Tiffany ST, Christen AG. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob Res. 2001;3:7-16.
11. Montgomery SA, A? sberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
12. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133: 429-435.
13. Posner K, Brown GK, Stanley B, et al. The Columbia Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266-1277.
14. Weinberger AH, Vessicchio JC, Sacco KA, et al. A preliminary study of sustained-release bupropion for smoking cessation in bipolar disorder. J Clin Psychopharmacol. 2008;28:584-587.
15. Kohen I, Kremen N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry. 2007;164: 1269-1270.
16. McClure JB, Swan GE, Catz SL, et al. Smoking outcome by psychiatric history after behavioral and varenicline treatment. J Subst Abuse Treat. 2010;38: 394-402.
17. Williams JM, Anthenelli RM, Morris CD, et al. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2012;73:654-660.